Whitehawk Therapeutics (WHWK) Accumulated Depreciation & Amortization (2018 - 2025)
Whitehawk Therapeutics (WHWK) has disclosed Accumulated Depreciation & Amortization for 7 consecutive years, with $368000.0 as the latest value for Q2 2025.
- On a quarterly basis, Accumulated Depreciation & Amortization changed 0.27% to $368000.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $368000.0, a 0.27% change, with the full-year FY2024 number at $193000.0, up 14.2% from a year prior.
- Accumulated Depreciation & Amortization was $368000.0 for Q2 2025 at Whitehawk Therapeutics, up from $193000.0 in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $369000.0 in Q2 2024 to a low of $38000.0 in Q1 2023.
- A 5-year average of $149615.4 and a median of $113000.0 in 2022 define the central range for Accumulated Depreciation & Amortization.
- Peak YoY movement for Accumulated Depreciation & Amortization: plummeted 48.65% in 2023, then soared 355.56% in 2024.
- Whitehawk Therapeutics' Accumulated Depreciation & Amortization stood at $105000.0 in 2021, then soared by 51.43% to $159000.0 in 2022, then rose by 6.29% to $169000.0 in 2023, then rose by 14.2% to $193000.0 in 2024, then skyrocketed by 90.67% to $368000.0 in 2025.
- Per Business Quant, the three most recent readings for WHWK's Accumulated Depreciation & Amortization are $368000.0 (Q2 2025), $193000.0 (Q4 2024), and $369000.0 (Q2 2024).